Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables the rapid and precise refinement of structural drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA.
Investor insights
Funding rounds participated in
$200M sweet spot round size
Investor type
Basic info
Industry
Sectors
Funding rounds raised
Total raised
$200M
from 2 investors over 1 rounds
Tyra Biosciences raised $200M on March 2, 2024
Investors: RA Capital Management and + 4 Other investors